Recent Updates
Recently added Catalysts
BMEA Positive Sentiment

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Tuesday, October 21, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Biomea Fusion, Inc. will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on October 23, 2025. The event will feature a live audio webcast available on their website. Biomea specializes in developing oral therapies for diabetes and obesity, addressing critical metabolic disorders.
Price reaction · baseline $1.59 (2025-10-21 close) · hit after-hours · 1 other BMEA headline(s) in the window, move may be shared
day 0 close
-9.4%
day 1 · peak
-13.2%
day 3
-10.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Biomea Fusion is actively participating in industry discussions.
  • The company is focused on developing transformative therapies for diabetes and obesity.
  • Their mission targets a significant global health challenge.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
7.7%
average across 12 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
icovamenib
Phase 2 · Type 2 Diabetes

Full Press Release Details

SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time.
A live audio webcast of the discussion will be availablehereor by visiting the Investors & Media section of Biomea’s website athttps://investors.biomeafusion.com/news-events/events. A replay of the webcast will be available following the live event.
About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at biomeafusion.com and follow us onLinkedIn,XandFacebook.

Contact:Meichiel Jennifer WeissSr. Director of Investor Relations and Corporate Developmentir@biomeafusion.com

Frequently Asked Questions

When will Biomea Fusion participate in the fireside chat?

Biomea Fusion will participate on October 23, 2025, at 8:00 a.m. PT.

How can I access the webcast of the event?

The live audio webcast can be accessed through Biomea's Investors & Media section.

What is the focus of Biomea Fusion's therapies?

Biomea Fusion focuses on developing therapies for diabetes and obesity.

What is Biomea Fusion's mission?

Their mission is to deliver transformative treatments for patients with diabetes and obesity.

ShareAdd on Google
Tags: BMEA Viatris Investor Conferences Healthcare Biomea Fusion Citi biotech diabetes obesity
Last updated: Oct 21, 2025

Biotech snapshot

Cash runway
$35M liquidity · $3M/mo burn
~10 mo
Medium dilution risk
Lead asset
icovamenibPhase 2
Type 2 Diabetes →

Catalyst track record

+35%
best trade around BMEA's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for BMEA.

See every catalyst's timing & PoA →